2012	- Indoco announced the signing of an agreement with DSM, a € 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO.
2011	- Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (Himachal\Pradesh) at IDMA's Golden Jubilee celebrations.
2010	- Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia.
	- Indoco Remedies licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of profit sharing agreement, Indoco will develop, manufacture and supply a basket of sterile products to Watson for the US market.
2009	- UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant.
	- Export sales exceeded Rs. 1 Billion in the FY 08-09.
	- Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area.
2008	- IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award.
	- TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams & Ointments Dosage forms at GOA Plant I.
	- First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA.
	- Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant.
	- MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II.
2007	- ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I.
	- Commencement of exports to the US markets.
	- Launch of Warren-Excel and Spera - two specialty marketing divisions.
2006	- US-FDA approval for Ophthalmic facility, Plant-II in GOA.
	- Contract signed for supply of 18 generic products to German Market.
	- 2 ANDAs filed with USFDA.
	- Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh.
	- New R&D Centre at Rabale, near Mumbai becomes functional.
	- Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA.
	- UK-MHRA approval for Creams & Ointments facility.
	- Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing.
	- Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards.
	- Launch of Surge - a specialty marketing division.
2005	- First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa.
	- Development Contracts for injectable products signed with a US Company.
	- Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant.
	- Shares of the Company listed on BSE and NSE.
2004	- First Contract for Development services with US Company.
	- Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd.
	- Four Patent applications filed.
	- Company jumps five ranks in two yrs in the ORG-IMS Retail Audit.
2003	- UK-MHRA approval for the Solid Dosage facility at Plant I.
	- Exports to regulated markets commence.
	- First contract for Dossier Development with European company.
	- Domestic Marketing makes a foray into the lifestyle segment.
2002	- State-of-the-art sterile facility, Plant II commissioned at Verna Goa.
1999	- New Corporate Office at Indoco House.
	- Acquisition of Warren, Company makes presence in Ophthalmic & Dental Segments.
1997	- Commencement of production in Goa Plant I.
1993	- R&D recognized by DSIR.